Access to Cancer Medicines in China: A Regional Snapshot
China rolled out a nationwide price‑cut initiative for drugs in 2016 to make cancer treatments cheaper and more accessible. While the program has enabled many patients to purchase life‑saving medicines, recent research reveals that its benefits are unevenly distributed across the country.
Key Findings
- Regional Disparities
- Coastal cities, with larger hospitals and greater funding, enjoy far better access to discounted drugs.
Interior towns and western border areas lag behind, struggling to obtain the same medications.
- Hospital-Level Variations
- Even within a single province, some hospitals receive more discounted drugs than others due to their connections with national supply chains.
Methodology
Researchers employed a decomposition analysis to untangle the causes of these gaps:
Funding Differences
- Wealthier regions receive higher reimbursements for drug purchases, boosting access.
Logistics and Storage
- Areas with superior distribution networks and storage facilities maintain safer, more readily available medicines.
Implications
- Price Cuts Alone Are Insufficient
Without additional support, the program risks widening existing health inequalities rather than mitigating them.
- Policy Recommendations
- Strengthen funding for poorer regions.
- Upgrade supply‑chain infrastructure to ensure equitable distribution of discounted drugs.
Conclusion
The study underscores the need for a balanced approach that goes beyond price reductions, addressing both financial and logistical barriers to create truly equitable access to essential medicines across China.
